India’s rural working class: peasantry and wage workers, Prof. Ramachandran said that the peasantry as a social group was enormously historically resilient and was a category that spans over ...

So the next time you feel doomed and hopeless, just remember you have more power than you think — and that's not spiritual mumbo jumbo; it's literal neuroscience!

Nancy’s contributions to neuroscience have been widely recognized, earning her a Fellowship in the Royal Society. But how might her work on brain inflammation inform our understanding of other ...

This worked in both groups, suggesting "there's a reliable signal in that part of the brain, that primary visual cortex, which is pictorial," even among people with aphantasia, Pearson said.

If one poster seems like a way for Vijay to thank his fans for being his backbone, the other pays an ode to the late MG Ramachandran ... first look poster) Vijay's new poster from Jana Nayagan ...

Yenisel Cruz-Almeida receives funding from the National Institutes of Health. She is an Associate Editor at the Journal of Pain and serves as Treasurer on the US Association for the Study of Pain.

Nobody likes to feel pain, but it’s something every person will experience at some point in their life. But why is that? I am a neuroscientist, and my job is to research why and how people feel ...

Millionaire Bryan Johnson, known for his anti-ageing efforts, has locked horns with neuroscientist Andrew Huberman on social media over the latter's remark on Johnson’s exercise video.

Mr. Piller is an investigative journalist for Science. This essay is adapted from his upcoming book, “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s.” Jan. 24, 2025 ...

Shares of Vigil Neuroscience (NASDAQ:VIGL) rose ~18% in the premarket on Thursday after the Sanofi (SNY)-backed biotech said that it expects to advance its Alzheimer's candidate VG-3927 into a ...

WATERTOWN, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...

Vigil Neuroscience plans a Phase 2 trial for Alzheimer's in Q3 2025, advancing a once-daily 25mg oral dose. Get two weeks of free access to pro-level trading tools, including news alerts ...